Hermetica Superfood Encyclopedia
The Short Answer
Akpalata bark contains a complex mixture of flavonoids, phenolics, alkaloids, terpenoids, and coumarins—most notably the flavanone eriodictyol—which exert antioxidant, antimicrobial, and antiplasmodial effects through free radical scavenging, microbial membrane disruption, and synergistic antibiotic potentiation. The most quantified preclinical finding is eriodictyol's radical-scavenging potency (DPPH SC₅₀ 2.51 ± 0.06 µg/mL; ABTS SC₅₀ 2.14 ± 0.05 µg/mL) and a methanol bark extract antiplasmodial IC₅₀ of 2.97 µg/mL against Plasmodium falciparum 3D7 strain in vitro, though no human clinical trials have confirmed these effects.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary Keywordakpalata benefits
Akpalata — botanical close-up
Health Benefits
**Antioxidant Activity**
Eriodictyol isolated from bark demonstrates potent radical scavenging with ABTS SC₅₀ of 2.14 ± 0.05 µg/mL and DPPH SC₅₀ of 2.51 ± 0.06 µg/mL, suggesting the flavonoid-phenolic fraction may neutralize reactive oxygen species and reduce oxidative stress-associated cellular damage.
**Antimicrobial and Antifungal Effects**
Bark fractions disrupt bacterial and fungal cell membranes of pathogens including Salmonella typhi, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and fluconazole-resistant Candida albicans, with synergistic fractional inhibitory concentration indices (FICI ≤ 0.5) observed when combined with ciprofloxacin, tetracycline, fluconazole, or ketoconazole.
**Antiplasmodial Action**
Methanol bark extract inhibits Plasmodium falciparum 3D7 growth in vitro with an IC₅₀ of 2.97 µg/mL, an activity attributed to phenolics, steroids, coumarins, alkaloids, and flavonoids in bioassay-guided active fractions that likely disrupt parasite metabolic processes.
**Anti-inflammatory Properties**
Ethnopharmacological use for rheumatism, lumbago, and fever is supported by in vitro evidence that phenolic and flavonoid constituents modulate inflammatory mediators, consistent with traditional use patterns documented across West Africa.
**Hepatoprotective and Nephroprotective Effects**
Animal and in vitro models indicate that bark extracts reduce liver enzyme markers ALT and AST and kidney biomarkers urea and creatinine, suggesting an organ-protective role potentially mediated by antioxidant and anti-inflammatory constituents.
**Antibiotic Potentiation**
Bark fractions exhibit additive-to-synergistic interactions with standard antibiotics (ciprofloxacin, tetracycline) and antifungals (fluconazole, ketoconazole) against multi-drug-resistant organisms, suggesting utility as a resistance-modifying adjunct through mechanisms such as efflux pump inhibition or enhanced membrane permeability.
**Anthelmintic and Analgesic Uses**
Traditional applications for hernia-associated pain and parasitic infections are documented across Nigerian and West African ethnomedicine, though molecular targets for these activities have not been formally characterized beyond general cytotoxic and anti-inflammatory properties of the alkaloid and terpenoid fractions.
Origin & History
Natural habitat
Afzelia africana is a large deciduous legume tree native to the tropical savanna woodlands and Guinea-Congolian forests of sub-Saharan Africa, distributed across Nigeria, Cameroon, Ghana, Senegal, and extending into East Africa. It thrives in well-drained lateritic soils at low to mid elevations, tolerating seasonal drought, and is commonly found at forest margins and riverine zones. The tree is not formally cultivated as an agricultural crop; bark, seeds, leaves, and roots are harvested from wild populations by traditional healers and local communities.
“Afzelia africana has been employed for centuries in West and Central African traditional medicine systems, with the bark being the most widely used part across Nigeria, Ghana, Cameroon, and Senegal for treating gonorrhea, hernia, lumbago, rheumatism, fever, malaria, and internal parasites. In Yoruba and Igbo ethnomedicine (Nigeria), the tree is called 'akpalata' and decoctions of its bark or root are administered orally or as topical poultices depending on the condition being treated. The seeds, known locally as 'African mahogany bean' or 'doussié seed,' are used as food adjuncts in some communities and incorporated into soups and porridges. The tree itself holds cultural significance beyond medicine—its extremely hard, durable timber is prized for construction and carving, and the tree appears in local folklore as a symbol of strength and endurance across multiple West African ethnic traditions.”Traditional Medicine
Scientific Research
The entire evidence base for Afzelia africana consists of in vitro phytochemical screening, gas chromatography of bark fractions, in vitro antimicrobial minimum inhibitory concentration (MIC) and FICI assays, in vitro antiplasmodial IC₅₀ determination against P. falciparum 3D7, and limited animal organ-toxicity biomarker studies—no randomized controlled trials, cohort studies, or any human clinical data exist in the published literature. Gas chromatography has identified 88–95 distinct secondary metabolites across bark extract fractions, and bioassay-guided fractionation (F1–F4) has partially characterized which compound classes drive each bioactivity, but no single compound has been fully pharmacokinetically characterized. Antioxidant SC₅₀ values for eriodictyol and antiplasmodial IC₅₀ data represent the most rigorously quantified findings, yet absence of in vivo pharmacokinetic or pharmacodynamic studies means translation to human efficacy cannot be assumed. The volume of published research is sparse—fewer than a handful of peer-reviewed studies are available—and none meet the methodological standards required to establish clinical therapeutic claims.
Preparation & Dosage
Traditional preparation
**Traditional Bark Decoction**
Bark is boiled in water and consumed as a tea or applied topically; no standardized volumes or concentrations are documented in ethnomedicinal literature.
**Crude Methanol Extract (Research Use Only)**
Used in laboratory studies at concentrations yielding IC₅₀ values in the low µg/mL range; not applicable to human supplementation without formulation development and safety studies.
**Bioassay-Guided Fractions (F1–F4)**
Prepared by column chromatography from methanol extracts, yielding flavonoid-, terpenoid-, phenolic-, and steroid-enriched fractions; these are experimental tools only and have no established human dosage.
**Seed Preparations**
Seeds are consumed locally as food supplements given high biochemical content; exact nutrient or phytochemical doses from seed consumption are not quantified in available literature.
**No Standardized Supplement Form Exists**
No commercial capsule, tablet, tincture, or standardized extract is documented; no effective dose ranges, timing recommendations, or standardization percentages have been established from clinical data.
**Caution**
All preparation and dosage information is derived from traditional practice or preclinical research; no safe or effective human dose has been clinically validated.
Nutritional Profile
Detailed proximate composition data for Afzelia africana parts as consumed by humans are not formally published in the available literature; seeds are reported to contain meaningful levels of steroids, flavonoids, tannins, saponins, and phytate (anti-nutritional factor that can reduce mineral bioavailability by chelating iron, zinc, and calcium). Leaves contain steroids at levels higher than roots, with roots reported at approximately 5.23 ± 0.23 mg/g, but lipid, protein, carbohydrate, and caloric compositions have not been quantified in peer-reviewed proximate analyses. Bark fractions are rich in secondary metabolites—alkaloids, anthraquinones, flavonoids (notably eriodictyol), phenolic acids, coumarins, glycosides, terpenoids, and tannins—with 88–95 distinct compounds identified by gas chromatography across polar and non-polar fractions. Bioavailability of any specific constituent after oral ingestion has not been assessed via pharmacokinetic studies in humans or animals, and the presence of tannins and phytate in seed fractions suggests potential inhibition of mineral absorption if consumed in significant quantities.
How It Works
Mechanism of Action
The primary antioxidant mechanism involves eriodictyol and other bark flavonoids donating hydrogen atoms to neutralize ABTS and DPPH radicals, with the catechol B-ring of eriodictyol providing electron-rich sites for free radical quenching. Antimicrobial activity is attributed to phenolics, saponins, and terpenoids disrupting bacterial and fungal plasma membrane integrity, increasing permeability and causing leakage of intracellular contents; synergy with antibiotics (FICI ≤ 0.5) suggests secondary mechanisms including efflux pump inhibition or compromised outer membrane barrier function in Gram-negative organisms. Antiplasmodial activity (IC₅₀ 2.97 µg/mL against P. falciparum 3D7) is attributed to the combined action of phenolics, alkaloids, steroids, and coumarins in active chromatographic fractions, with coumarins and alkaloids hypothesized to intercalate into parasite DNA or inhibit heme polymerization, consistent with known mechanisms of structurally related compounds. No gene expression profiling, receptor binding assays, or enzyme kinetics studies specific to Afzelia africana constituents have been published, so all molecular pathway assignments remain inferential.
Clinical Evidence
No human clinical trials investigating Afzelia africana or akpalata preparations for any indication have been conducted or reported in the available scientific literature as of the current knowledge base. All mechanistic and efficacy data derive from in vitro cell-free assays (DPPH, ABTS, MIC, FICI, P. falciparum IC₅₀) and animal toxicity biomarker studies, which, while hypothesis-generating, do not constitute clinical evidence. Effect sizes such as eriodictyol DPPH SC₅₀ of 2.51 µg/mL and antiplasmodial IC₅₀ of 2.97 µg/mL are promising in the preclinical context but have not been validated with dose-response studies in humans, and no pharmacokinetic data confirm bioavailability of active constituents after oral administration. Confidence in clinical application for any of the traditional indications—gonorrhea, hernia, malaria, fever—is very low, and formal clinical investigation with defined extract preparations, standardized doses, and validated endpoints is required before therapeutic recommendations can be made.
Safety & Interactions
No formal human safety studies, dose-escalation trials, or adverse event reporting exist for Afzelia africana preparations; traditional use across West Africa is the primary basis for assumed tolerability, but this does not establish a proven safety profile. In vitro and animal model data suggest hepatoprotective and nephroprotective effects (reduced ALT, AST, urea, creatinine), indicating absence of acute organ toxicity at studied concentrations, though chronic safety has not been evaluated. The most clinically relevant interaction signal is synergy—not antagonism—with antibiotics (ciprofloxacin, tetracycline) and antifungals (fluconazole, ketoconazole), meaning co-administration could theoretically potentiate antimicrobial effects or alter drug pharmacodynamics; one exception is minor antagonism of eriodictyol with ciprofloxacin against P. aeruginosa. Phytate content in seeds poses a risk of mineral deficiency (iron, zinc, calcium) with high-dose or long-term consumption; pregnancy and lactation safety is entirely unstudied, and use should be avoided in these populations until data are available.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Afzelia africanaAfrican mahogany beanDoussiéAkparataLenke (Senegal)Papao (Ghana)
Frequently Asked Questions
What is akpalata used for in traditional African medicine?
In West African ethnomedicine, akpalata (Afzelia africana) bark is traditionally used to treat gonorrhea, hernia, malaria, fever, rheumatism, lumbago, and internal parasitic infections. Preparations typically involve boiling the bark to make a decoction consumed orally or applied topically, with the specific formulation varying by condition and regional practice across Nigeria, Ghana, Cameroon, and Senegal.
Does akpalata have scientifically proven antimicrobial activity?
In vitro studies show that Afzelia africana bark fractions inhibit Salmonella typhi, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and fluconazole-resistant Candida albicans, with synergistic activity (FICI ≤ 0.5) when combined with antibiotics like ciprofloxacin and tetracycline. However, these findings are limited to laboratory cell-culture assays and have not been validated in human clinical trials, so antimicrobial efficacy in people cannot be confirmed from current evidence.
What are the main bioactive compounds in Afzelia africana bark?
Gas chromatography has identified 88–95 secondary metabolites in Afzelia africana bark extract fractions, including alkaloids, anthraquinones, flavonoids, phenolic acids, coumarins, glycosides, terpenoids, steroids, tannins, and saponins. The most characterized single compound is eriodictyol, a flavanone with potent antioxidant activity (DPPH SC₅₀ 2.51 ± 0.06 µg/mL; ABTS SC₅₀ 2.14 ± 0.05 µg/mL) isolated from the bark via bioassay-guided fractionation.
Is akpalata safe to use, and are there known drug interactions?
No formal human safety or toxicology studies exist for akpalata preparations; traditional use provides only anecdotal tolerability data. The most important documented interaction signal is synergy with antibiotics (ciprofloxacin, tetracycline) and antifungals (fluconazole, ketoconazole), which could amplify drug effects unpredictably; one minor antagonistic interaction was observed between eriodictyol and ciprofloxacin against P. aeruginosa. Use during pregnancy or lactation is not recommended due to a complete absence of safety data in these populations.
What is the antiplasmodial potency of Afzelia africana extract?
A methanol bark extract of Afzelia africana exhibited an IC₅₀ of 2.97 µg/mL against the Plasmodium falciparum 3D7 strain in an in vitro antiplasmodial assay, with the most active chromatographic fractions containing phenolics, steroids, coumarins, and alkaloids. This preclinical result is promising but has not been advanced to animal efficacy models or human malaria trials, so it cannot be translated into a treatment recommendation.
How does akpalata's antioxidant potency compare to other herbal sources?
Akpalata bark contains eriodictyol with ABTS and DPPH scavenging activity (SC₅₀ values of 2.14 and 2.51 µg/mL respectively), placing it among potent natural antioxidants comparable to established botanical standards. The flavonoid-phenolic fraction demonstrates strong radical-scavenging capacity that suggests meaningful potential for reducing oxidative stress at cellular levels. Direct comparative studies against other recognized antioxidant herbs would further clarify its relative efficacy in supplement formulations.
What is the difference between akpalata bark extract and whole plant preparations?
Akpalata bark extracts concentrate bioactive compounds like eriodictyol and the antimicrobial/antifungal agents found in bark fractions, potentially offering more standardized potency than whole plant preparations. Bark-specific extracts provide targeted delivery of the well-researched phenolic and flavonoid compounds responsible for antioxidant and antimicrobial activity. Whole plant preparations may include additional compounds from leaves and roots but typically lack the concentrated bioactive profile and standardization of bark extracts.
What does current research reveal about akpalata's effectiveness for oxidative stress-related conditions?
In vitro studies demonstrate that eriodictyol from akpalata bark exhibits potent free radical scavenging activity, suggesting theoretical benefit for oxidative stress reduction and cellular protection. However, most existing evidence is based on laboratory assays rather than human clinical trials, limiting definitive claims about real-world efficacy for specific health conditions. Further research translating these in vitro findings into clinical outcomes would strengthen the evidence base for akpalata supplementation targeting oxidative damage.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w akpalata-afzelia-africana curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
